Plain-English translation of NCT04944914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a type of focused radiation called stereotactic body radiotherapy to (an immunotherapy drug) works better than alone for patients with nasopharyngeal cancer that has spread to a small number of distant sites. You would have already completed standard treatment for your primary cancer before joining. The goal is to see if combining these two approaches can help more patients achieve long-term control of their disease.
Some patients with advanced nasopharyngeal cancer develop only a few scattered spots of cancer spread rather than widespread disease. This trial is exploring whether treating these specific spots with radiation while also giving immunotherapy might cure some patients who would otherwise face a poor outcome.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: one group receives the immunotherapy drug by IV infusion every 2 weeks plus stereotactic body radiation to all cancer spots, while the other group receives the immunotherapy alone. Both treatments continue for up to 1 year, unless your disease gets worse, you experience unacceptable side effects, or your doctor decides to stop. You would have regular imaging scans and check-ups to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China